Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report

Lu Yin, BA, Prince Adotama, MD, Katerina Svigos, BA, Daniel Gutierrez, MD, and Kristen Lo Sicco, MD

New York, New York

Key words: pigmentary disorder; platelet-rich plasma; skin of color; vitiligo.

INTRODUCTION

Vitiligo is an autoimmune disorder that targets and destroys melanocytes, resulting in skin depigmentation. As a potentially highly visible condition, vitiligo may be stigmatizing and distressing for patients. Platelet-rich plasma (PRP) contains high concentrations of platelets and growth factors and is an increasingly popular treatment for androgenetic alopecia. While the use of PRP to treat androgenetic alopecia has been documented, its utility in treating vitiligo is still in the initial stages of investigation. Here, we present the case of a 39-year-old male who had improvement in his vitiligo after phototherapy and PRP injections.

CASE REPORT

A 39-year-old male with a 26-year history of nonsegmental vitiligo presented for PRP therapy. His family history included a grandfather with vitiligo, but he had no personal or family history of other autoimmune disorders. Laboratory testing revealed a normal thyroid-stimulating hormone level. The patient began vitiligo treatment 2 months prior with narrowband ultraviolet B (NB-UVB) phototherapy 3 times per week and the application of 1% pimecrolimus cream twice daily on his face. NB-UVB treatment was initiated at 300 mJ/cm² on the body, increased by 50 mJ/cm² per visit, and 100 mJ/cm² on the face, increased by 25 mJ/cm² per visit. The treatments were well tolerated and resulted in repigmentation on his bilateral upper extremities. However, he had minimal changes to his head and neck after 17 treatments. Depigmented patches were present on the periorbital, perinasal, and perioral skin and on the bilateral temples and frontal scalp (Fig 1). Minimal perifollicular pigment was noted on dermoscopic evaluation of the head and neck, and, notably, starburst pattern, micro-Koebner phenomenon, and altered pigment network were not observed (Fig 1). Given these minimal changes, he elected treatment with PRP and halted facial therapy with pimecrolimus.

Whole blood was drawn using the RegenKit Blood Cell Therapy and centrifuged for 5 minutes using the Drucker 642VFD-Plus centrifuge (Regen Lab). Each injection, spaced 1 cm apart, contained 0.1 mL of PRP. The patient received a total of 6 mL of PRP, with approximately 3 mL injected along the frontal and temporal regions of the scalp in the areas of depigmented patches. Concomitant treatment with PRP injections (monthly, total 3 treatments) and NB-UVB (3 times a week) was continued for 2 months, resulting in >50% improvement over baseline (good response), involving his eyelids and eyebrows, frontal region of the scalp, and temples (Fig 1). Owing to the coronavirus disease 2019 pandemic, he temporarily discontinued phototherapy for 6 weeks. Upon his return to the clinic, he demonstrated continued repigmentation with >75% improvement from baseline (excellent response) on the face and scalp, without any specific signs of vitiligo worsening on dermoscopy (Fig 1). Although PRP

From The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine

Authors Yin, Adotama, Svigos, Gutierrez, and Lo Sicco contributed equally to this article.

Abbreviations used:

NB-UVB: narrowband ultraviolet B
PRP: platelet-rich plasma

School of Medicine, 240 East 38th Street, 12th Floor, New York, NY 10016. E-mail: kristen.losicco@nyulangone.org.

JAAD Case Reports 2020;6:1320-2.
2352-5126
© 2020 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2020.09.021
induces microtrauma in the skin, there were no clinical or dermoscopic signs of koebnerization in our patient.

DISCUSSION

Phototherapy treats vitiligo through melanocyte stimulation, migration, and increased melanin production and begins to affect the autoimmune pathway of the disease process over time. While these strategies are effective, alternative therapeutic interventions such as PRP offer a regenerative treatment approach, fostering a fertile environment rich in growth factors and cytokines to help promote and restore normal cellular function. In addition to melanocytes, keratinocytes and fibroblasts as well as a multitude of inflammatory pathways are involved in vitiligo pathogenesis, and subsequent PRP stimulation of various factors may promote the differentiation, proliferation, and maturation of melanocytes and keratinocytes, leading to epidermal repigmentation.

Previous studies have found intradermal PRP injections to be an effective adjunctive therapy, when used concomitantly with light and laser therapies. An open-label split-body trial comparing NB-UVB alone to NB-UVB with PRP in 60 Egyptian patients with stable nonsegmental symmetric vitiligo
demonstrated that 75% of patients in the NB-UVB with PRP group exhibited a good or excellent response after 4 months, whereas none of those in the NB-UVB-alone group exhibited similar response rates. One study has shown that PRP monotherapy had poor results compared with a fractional CO₂ and PRP combination, which exhibited much more significant repigmentation rates.

Another study found that stable nonsegmental vitiligo patients treated with PRP and excimer laser (308 nm) achieved a greater response than the excimer laser-alone group (84.6% versus 34.6% good or excellent response).

Our report of a vitiligo patient who demonstrated an excellent response to the treatment with concomitant PRP injections and NB-UVB for his depigmented facial patches adds to the growing literature on PRP as a potential novel adjunctive therapy for vitiligo. After 17 phototherapy treatments, our patient had repigmentation on his bilateral extremities but did not exhibit repigmentation of his depigmented facial patches. A previous study demonstrated that initial facial repigmentation may be seen after an average of 16 NB-UVB treatments in vitiligo patients with <10% body surface area involvement, and patients with facial lesions tend to be more responsive to phototherapy. Our patient did not exhibit a significant response to NB-UVB alone on his face despite >16 sessions of NB-UVB, which suggests that the addition of PRP had an additional treatment effect.

Of note, no koebnerization or other major adverse events were noted in our patient, which is consistent with the minimal side effects reported after PRP treatment in the aforementioned studies.

Currently, there are a few studies in the literature investigating the adjunctive PRP treatment of vitiligo. Our report contributes to the existing literature the case of a patient who exhibited facial repigmentation with concomitant PRP and phototherapy treatment, supporting the previous reports that PRP may be a promising adjunctive treatment modality for vitiligo. Larger prospective controlled studies are needed to fully assess its potential role in vitiligo treatment.

REFERENCES
1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84.
2. Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017;35(2):117-128.
3. Ho A, Sukhdeo K, Lo Sicco K, Shapiro J. Trichologic response of platelet-rich plasma in androgenetic alopecia is maintained during combination therapy. J Am Acad Dermatol. 2020;82(2):478-479.
4. Khattab FM, Abdelbary E, Fawzi M. Evaluation of combined excimer laser and platelet-rich plasma for the treatment of nonsegmental vitiligo: a prospective comparative study. J Cosmet Dermatol. 2020;19(4):869-877.
5. Ibrahim ZA, El-Ashmawy AA, El-Tatawy RA, Salam FA. The effect of platelet-rich plasma on the outcome of short-term narrowband-ultraviolet B phototherapy in the treatment of vitiligo: a pilot study. J Cosmet Dermatol. 2016;15(2):108-116.
6. Abdelghani R, Ahmed NA, Darwish HM. Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: a prospective, randomized comparative trial. J Cosmet Dermatol. 2018;17(3):365-372.
7. Goldstein NB, Koster MI, Hoaglin LG, et al. Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol. 2015;135(8):2068-2076.
8. Barbulescu CC, Goldstein NB, Roop DR, Norris DA, Birlea SA. Harnessing the power of regenerative therapy for vitiligo and alopecia areata. J Invest Dermatol. 2019;140(1):29-37.
9. Welsh O, Herz-Ruelas ME, Gómez M, Ocampo-Candiani J. Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects less than 10% of the body surface area. Int J Dermatol. 2009;48(5):529-534.
10. Nicolaïdou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56(2):274-278.